WO2026139920 - STABILISED HERPESVIRUS ANTIGENS
National phase entry is expected:
Publication Number
WO/2026/139920
Publication Date
02.07.2026
International Application No.
PCT/IB2025/063443
International Filing Date
24.12.2025
Title **
[English]
STABILISED HERPESVIRUS ANTIGENS
[French]
ANTIGÈNES DU VIRUS DE L'HERPÈS STABILISÉS
Applicants **
THE HOSPITAL FOR SICK CHILDREN
Inventors
JULIEN, Jean-Philippe
HEIDE, Fabian
KELLAM, Paul
Priority Data
2419071.2
24.12.2024
GB
2419072.0
24.12.2024
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4275 | |
| EPO | Filing, Examination, Granting | 25879 | |
| Japan | Filing, Examination, Granting | 2653 | |
| South Korea | Filing, Examination, Granting | 3165 | |
| USA | Filing, Examination, Granting | 11940 |
Total:
47,912
Contact Us
Abstract[English]
Stabilised Herpesvirus antigens The invention relates to stabilised Herpesvirus antigens, including Herpesvirus glycoprotein B (gB) antigens comprising a non-native Membrane Proximal Region (MPR), use of non-native MPR structures to stabilise the Herpesvirus gB in its pre-fusion form, and methods for designing non-native MPR structures. The invention further relates to a stabilised Herpesvirus gB for use as an immunogen, immune reagent or a vaccine.[French]
L'invention concerne des antigènes du virus de l'herpès stabilisés, comprenant des antigènes de glycoprotéine B du virus de l'herpès (gB) comprenant une région proximale de membrane non native (MPR), l'utilisation de structures MPR non natives pour stabiliser le virus de l'herpès gB sous sa forme de pré-fusion, et des procédés de conception de structures MPR non natives. L'invention concerne en outre un virus de l'herpès gB stabilisé destiné à être utilisé en tant qu'immunogène, réactif immunitaire ou vaccin.